Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a maintenance/versioning update that does not modify the study details or other substantive content on the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 was added and the funding-lapse notice (v3.4.1) was removed. There are no changes to the core study details, eligibility criteria, or outcomes.SummaryDifference0.5%

- Check41 days agoChange DetectedNotice about a lapse in government funding is added, informing users that the site may not be up to date and inquiries may be delayed, along with a status note about the NIH Clinical Center's operating status; the page revision changed from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check48 days agoChange DetectedMinor UI and metadata updates were made: glossary toggle visibility added, Last Update Submitted that Met QC Criteria label updated, No FEAR Act Data capitalization adjusted, and a new revision tag v3.4.0 introduced, with older items like 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision v3.3.4 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check62 days agoChange DetectedThe revision label in the page footer changed from v3.3.3 to v3.3.4. No substantive content or functionality changes are observed in the screenshots.SummaryDifference0.1%

- Check83 days agoChange DetectedFooter updates: added 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.